Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation
Vito Di Lernia(Ospedale Santa Maria), Domenico Bonamonte(University of Milan), Cristina Guerriero(Foundation Center), Giampiero Girolomoni(University of Verona), Claudio Guarneri(University of Messina), Angela Filoni(University of Bari Aldo Moro), Claudia Lasagni(University of Modena and Reggio Emilia), Oriana Simonetti(Marche Polytechnic University), Luca Stingeni(University of Perugia), Serafinella Patrizia Cannavò(University of Messina), Anna Belloni Fortina(University of Padua), Iria Neri(Azienda USL di Bologna), Gaia Moretta(Università Cattolica del Sacro Cuore), Arianna Zangrilli(University of Rome Tor Vergata), Paolo Gisondi(University of Verona), Luca Bianchi(University of Rome Tor Vergata), Katharina Hansel(University of Ferrara), Dahiana M. Casanova(Azienda Sanitaria Unità Locale di Reggio Emilia)
Cited by 34
Related Papers
Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study
|Journal of Investigative Dermatology|2005|644
Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions
|The Journal of Immunology|2001|553
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
|Multiple Sclerosis Journal|2015|298
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients
|Journal of the European Academy of Dermatology and Venereology|2020|248
Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial
|Arthritis & Rheumatism|2011|216